









Markets
/
Stocks
/
nasdaq-clgn
/

Collplant Biotechnologies Ltd

CLGN

2.515USD

-0.125-4.73%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

31.98MMarket Cap

LossP/E TTM



Collplant Biotechnologies Ltd

2.515

-0.125-4.73%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

169 / 506

Overall Ranking

280 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.500

Target Price

+335.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 72.24% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 515.00K.

Fairly Valued

The company’s latest PE is -2.23, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 5.52M shares, increasing 3.08% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 41.60K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.72.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.50, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 179.00K, representing a year-over-year decrease of 28.11%, while its net profit experienced a year-over-year decrease of 20.50%.

Score

Industry at a Glance

Previous score

6.50

Change



Financials

8.84

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.68

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.34, which is -21.98% below the recent high of -1.83 and -0.76% above the recent low of -2.36.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 169/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Collplant Biotechnologies Ltd is 11.50, with a high of 12.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.500

Target Price

+335.61%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Collplant Biotechnologies Ltd

CLGN

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.34, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 3.09 and the support level at 2.06, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.34

Change

-0.86

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.058

Neutral

RSI(14)

47.199

Neutral

STOCH(KDJ)(9,3,3)

43.007

Neutral

ATR(14)

0.168

Low Volatility

CCI(14)

-151.795

Sell

Williams %R

72.555

Sell

TRIX(12,20)

0.177

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

2.597

Sell

MA10

2.634

Sell

MA20

2.653

Sell

MA50

2.470

Buy

MA100

2.164

Buy

MA200

2.763

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 43.39%, representing a quarter-over-quarter decrease of 7.68%. The largest institutional shareholder is James Simons, holding a total of 41.60K shares, representing 0.33% of shares outstanding, with 253.62% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Sagy (Ami)

1.94M

St. Denis J. Villere & Company, LLC

483.87K

Pinnacle Associates Ltd.

489.19K

-0.10%

Evans (Hugh M)

377.43K

-0.00%

Roumell Asset Management, L.L.C.

276.43K

-12.32%

Loewenbaum (Lilian Shaw)

275.74K

+34.08%

AMH Equity, Ltd.

125.00K

+7.30%

Brown Advisory

111.20K

-6.92%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.07, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.79. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.